Colorcon launches SoteriaRx on-dose authentication technology platform
Smart medications that can provide traceability from plant to patient.
A new platform of innovative on-dose technologies and detection services for authenticating medications that will help to protect patients and uphold brand integrity has come onto the market.
Counterfeit drugs, which are estimated to be worth US$200 billion or 2% of total pharma revenue, financially affect the pharmaceutical industry and compromise patient safety.
Traceability and security measures focused at the packaging level are insufficient to deter fraud, especially in low- and middle-income countries where either substandard or falsified medicines can account for up to 70% of medications distributed internally.
The solution is smart medications with on-dose taggants that can be authenticated throughout the supply chain. Colorcon's SoteriaRx provides a powerful tool for tracking medicines from plant to patient and provides a level of supply chain authenticity and transparency not previously available.
By incorporating microtags, the pill itself effectively becomes a barcode which can be digitally read and recorded, providing instant authentication.
According to Colorcon CEO, Martti Hedman, this digitalization of medicines represents a "major step forward" in the fight against unauthorized and illegitimate pharmaceutical production and provides an opportunity to safeguard patients.
Related News
-
News Axplora, the partner of choice for complex APIs
Latest newsletter from Axplora - API manufacturer -
Sponsored Content IFF Pharma Solutions: Paving the Way for Superior Suspensions
Shawn Branning, Global Strategic Marketing Manager at IFF – Pharma Solutions -
News Greenfield Global Ireland Ready to Supply Life Science Customers Globally
New facility aims to serve local and global pharmaceutical customers with high-purity ethanol, ethanol blends and buffer solutions -
News Rare diseases care pathway: a major challenge to harmonize patient management
In France, rare diseases are numerous: between 7,000 and 8,000 diseases are currently accounted for, and concern more than 3 million French people, accounting for almost 4,5% of the total population. The organization of screening and care for these ill... -
Sponsored Content CPHI Podcast Series: Selecting the Right CDMO Outsourcing Partner
Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and... -
Sponsored Content Sterile manufacturing Annex 1 amendments: what, why and how explained
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected... -
News Recipharm expands its analytical services offering in India
The CDMO inaugurates its new analytical laboratory under Recipharm Analytical Solutions -
News Tikun Olam-Cannbit and Wavelength strike novel cannabis agreement
Firms say the partnership will "multiply the power of both companies, the pharmaceutical industry and the medical cannabis industry"
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance